Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.74 -0.03 (-0.16%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines ↗
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
News headline image
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
News headline image
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues ↗
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
News headline image
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
News headline image
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? ↗
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this... 
Via Benzinga
News headline image
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024 ↗
Takeda Pharmaceutical just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
3 Biotech Stocks to Buy on the Dip: July 2024 ↗
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
News headline image
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
News headline image
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst ↗
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... 
Via Benzinga
News headline image
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma ↗
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... 
Via Talk Markets
News headline image
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report ↗
Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020. 
Via Benzinga
News headline image
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 ↗
Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
Via Investor's Business Daily
Topics Stocks
News headline image
Takeda Announces New Assignments of Directors
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? ↗
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. 
Via Benzinga
News headline image
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies ↗
Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes 
Via Benzinga
News headline image
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare ↗
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets
News headline image
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.